|  |  | Molecular subtyping | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 | All |  |  |  |  |  |  | Five subtypes | Four subtypes | |||||
Variables | (N = 951) | IHC-Luminal A (N = 486) | IHC-Luminal B (N = 123) | IHC-HER2 (N = 113) | IHC-BLBC (N = 139) | IHC-QNBC/5NP (N = 90) | IHC-TNBC (N = 229) | |||||||
 | HR(N of event) | HR(N of event) | HR(N of event) | HR(N of event) | HR(N of event) | HR(N of event) | HR(N of event) | |||||||
 | (95%CI) | p-value | (95%CI) | p-value | (95%CI) | p-value | (95%CI) | p-value | (95%CI) | p-value | (95%CI) | p-value | (95%CI) | p-value |
Age Group (yr) | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   < 50 | 1.00(85/590) |  | 1.00(22/297) |  | 1.00(14/87) |  | 1.00(21/51) |  | 1.00(17/97) |  | 1.00(11/58) |  | 1.00(28/155) |  |
   ≥ 50 | 0.99(52/361) |  | 1.43(20/189) |  | 1.42(8/36) |  | 0.32(9/62) |  | 0.92(7/42) |  | 1.23(8/32) |  | 1.08(15/74) |  |
 | (0.70-1.39) | 0.96 | (0.78-2.61) | 1.0 | (0.59-3.37) | 1.0 | (0.15-0.71) | 0.04 | (0.38-2.20) | 1.0 | (0.49-3.04) | 1.0 | (0.58-2.03) | 1.0 |
Tumor size (cm) | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   ≤ 2 cm | 1.00(28/392) | 0.005 | 1.00(7/228) |  | 1.00(5/39) |  | 1.00(6/35) |  | 1.00(6/52) |  | 1.00(4/38) |  | 1.00(10/90) |  |
   2-5 cm | 2.61(87/493) |  | 4.21(30/231) |  | 1.29(14/75) |  | 1.93(19/64) |  | 1.36(12/76) |  | 2.78(12/47) |  | 1.86(24/123) |  |
 | (1.70-4.00) | < 0.001 | (1.94-10.1) | 0.001 | (0.46-3.61) | 1.0 | (0.77-4.83) | 1.0 | (0.51-3.64) | 0.65 | (0.89-8.63) | 0.62 | (0.88-3.88) | 0.010 |
   > 5cm | 5.34(22/66) |  | 6.55(5/27) |  | 2.17(3/9) |  | 2.46(5/14) |  | 6.65(6/11) |  | 7.76(3/5) |  | 7.54(9/16) |  |
 | (3.05-9.33) | < 0.001 | (2.08-20.6) | 0.008 | (0.51-9.16) | 1.0 | (0.75-8.08) | 1.0 | (2.13-20.3) | 0.008 | (1.73-34.5) | 0.046 | (3.12-18.2) | < 0.001 |
LN involvement | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Negative | 1.00(39/498) |  | 1.00(7/246) |  | 1.00(7/52) |  | 1.00(12/63) |  | 1.00(8/89) |  | 1.00(5/48) |  | 1.00(13/137) |  |
   Positive | 2.93(98/453) |  | 4.88(35/240) |  | 1.55(15/71) |  | 2.23(18/50) |  | 4.6(16/50) |  | 3.96(14/42) |  | 3.99(30/92) |  |
 | (2.03-4.24) | < 0.001 | (2.25-10.45) | < 0.001 | (0.63-3.81) | 1.0 | (1.07-4.62) | 0.26 | (1.73-9.49) | 0.004 | (1.43-11.0) | 0.064 | (2.09-7.35) | < 0.001 |
AJCC stage | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   I | 1.00(10/254) |  | 1.00(0/148) |  | 1.00(2/19) |  | 1.00(3/22) |  | 1.00(2/38) |  | 1.00(3/27) |  | 1.00(5/65) |  |
   II | 3.29(58/467) |  | NA*(21/221) |  | 1.09(10/69) |  | 1.70(13/57) |  | 2.74(11/78) |  | 0.72(3/42) |  | 1.58(14/120) |  |
 | (1.68-6.43) | 0.001 |  |  | (0.23-5.01) | 1.0 | (0.48-5.97) | 1.0 | (0.61-12.3) | 1.0 | (0.14-3.58) | 1.0 | (0.57-4.40) | 1.0 |
   III | 8.74(69/230) |  | NA*(21/117) |  | 2.60(10/35) |  | 3.53(14/34) |  | 11.36(11/23) |  | 7.85(13/21) |  | 9.16(24/44) |  |
 | (4.50-16.9) | < 0.001 |  |  | (0.57-11.9) | 1.0 | (1.01-12.34) | 0.37 | (2.57-51.3) | 0.016 | (2.23-27.5) | 0.005 | (3.49-24.0) | < 0.001 |
Adjuvant chemotherapy | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Not done | 1.00(35/155) |  | 1.00(12/95) |  | 1.00(9/20) |  | 1.00(7/22) |  | 1.00(6/10) |  | 1.00(1/8) |  | 1.00(7/18) |  |
   Done | 0.59(102/796) |  | 0.74(30/391) |  | 0.23(13/103) |  | 0.75(23/91) |  | 0.17(18/129) |  | 2.23(18/82) |  | 0.41(36/211) |  |
 | (0.40-0.87) | 0.008 | (0.37-1.45) | 1.0 | (0.09-0.52) | 0.007 | (0.32-1.74) | 1.0 | (0.07-0.43) | < 0.001 | (0.29-16.7) | 1.0 | (0.18-0.93) | 0.06 |